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Abstract 
Monoclonal antibodies (mAbs) are key molecules in biopharmaceutical manufacturing with 
important therapeutic use such as anticancer drugs. Mammalian cells serve as production 
hosts for mAbs. However, mammalian cell culture processes are complex and development 
timelines for new processes are long. To overcome these challenges the industry is moving 
towards high-throughput, single-use bioreactors and intensified processes. The scalability in 
both directions (scale-down and scale-up) is a key step towards fast and economic process 
development. Moreover, novel Process Analytical Technology (PAT) tools aim at improving 
process understanding and establishing process control and automation resulting in high and 
consistent product quality. 
In the first part of this PhD thesis a method to transfer an existing Chinese Hamster Ovary 
(CHO) cell culture fed-batch process platform into a semi-perfusion process with threefold 
higher cumulative product titers was developed. Design of Experiment (DoE) as a powerful 
PAT tool to screen medium and feed compositions speeded up significantly the semi-perfusion 
process development. The process transfer to a small scale, single-use bioreactor enabled 
process control for important parameters such as pH and dissolved oxygen (DO) while keeping 
the experimental costs low. However, important process attributes (e.g. Viable Cell 
Concentrations (VCC)) were measured offline limiting the automation possibilities. 
The second part of this thesis demonstrated how the implementation of an advanced inline 
capacitance sensor can support online monitoring of important biomass related changes in cell 
culture. The sensor implementation was proven to be scale-independent in single-use 
bioreactors (50 L up to 2000 L). Additionally, the transferability of the method to different CHO 
fed-batch processes was demonstrated. The Wet Cell Weight (WCW) and Viable Cell Volume 
(VCV) were predicted for the complete cultivation duration within an acceptance criterion 
based on the offline reference method. The VCC, however, correlated with the permittivity 
signal only until the end of the exponential growth phase due to the single-frequency 
measurement dependency on cell diameter changes. 
The third part of this PhD thesis successfully tested the inline capacitance sensor in frequency 
scanning mode to predict VCCs over the complete culture time by establishing a robust 
Multivariate Data Analysis (MVDA) model. A small scale bioreactor system served as method 
development tool. Therefore, a fast and economic development of a robust MVDA model was 
demonstrated, highlighting the benefits of scale-down models in biopharmaceutical 
manufacturing. 
Key words: mammalian cell culture, single-use bioreactors, process analytical technologies 
(PAT), scalability
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Kurzfassung 
Monoklonale Antikörper sind Schlüsselmoleküle in biopharmazeutischen 
Herstellungsprozessen aufgrund ihres wichtigen therapeutischen Nutzens, wie beispielsweise 
als Antikrebs-Medikament. Tierzellkultivierungen dienen als Produktionswirt für monoklonale 
Antikörper. Tierzellkultivierungsprozesse sind jedoch komplex und Entwicklungszeiträume 
dauern lange an. Um diese Herausforderungen zu überwinden strebt die Industrie eine 
Entwicklung in Richtung Hochdurchsatz-, Einwegbioreaktoren und intensivierte Prozesse an. 
Die Skalierbarkeit in beide Richtungen (Runterskalierung und Hochskalierung) ist ein 
Schlüssel für schnelle und wirtschaftliche Prozessentwicklung. Des Weiteren ermöglichen 
neue Technologien zur Prozessanalytik (engl. Process Analytical Technology, PAT) ein 
verbessertes Prozessverständnis, Prozesskontrolle und Automation, sodass eine konstante 
und hohe Produktqualität gewährleistet wird.  
Im ersten Teil dieser Doktorarbeit wurde eine Methode entwickelt, um einen Chinese Hamster 
Ovary (CHO) Fed-Batch Zellkulturprozess in einen semi-Perfusionsprozess mit dreifach 
erhöhter kumulativer Produktausbeute zu übertragen. Statistische Versuchsplanung (engl. 
Design of Experiment, DoE) wurde als PAT Tool genutzt, um verschiedene Medium- und Feed-
Kompositionen zu untersuchen und führte zu einer signifikant schnelleren Entwicklung des 
semi-Perfusionsprozesses. Der Prozesstransfer zu einem kleinvolumigen Einwegbioreaktor 
ermöglichte die Prozesskontrolle wichtiger Parameter, wie pH und gelöstem Sauerstoff, mit 
geringen experimentellen Kosten. Wichtige Prozessattribute (z.B. Lebendzellzahl) wurden 
jedoch offline gemessen und führte zu einer Limitierung der Prozessautomation. 
Der zweite Teil der Arbeit zeigt, wie die Implementierung eines inline Kapazitätssensors das 
online-Monitoring wichtiger Biomasseänderungen in der Zellkultivierung unterstützt. Die 
Skalierungsunabhängigkeit des Sensors wurde in Einwegbioreaktoren mit Volumina von 50 L 
bis 2000 L erwiesen. Zusätzlich wurde die Übertragbarkeit der Methode auf andere CHO Fed-
Batch Prozesse dargelegt. Die Feuchtbiomasse und das lebensfähige Zellvolumen konnten 
über die gesamte Kultivierungsdauer innerhalb eines Akzeptanzkriteriums auf Basis der offline 
Referenz vorhergesagt werden. Die Lebendzellzahl korrelierte mit der Dielektrizitätskonstante 
aufgrund der Durchmesserabhängigkeit bis zum Ende der exponentiellen Wachstumsphase. 
Im dritten Teil der Doktorarbeit wurde der inline Kapazitätssensor im Scanning Modus 
evaluiert, um mit Hilfe eines multivariaten Datenmodells die Lebendzellzahl über den 
gesamten Kultivierungszeitraum vorherzusagen. Ein kleinvolumiger Bioreaktor diente zur 
Entwicklung der Methode. Aus diesem Grund konnte das robuste multivariate Modell schnell 
und wirtschaftlich entwickelt werden, was die Vorteile von kleinvolumigen Bioreaktoren in 
biopharmazeutischen Herstellungsprozessen hervorhebt.  
Schlagwörter: Tierzellkultivierung, Einwegbioreaktor, Technologien zur Prozessanalytik, 
Skalierbarkeit
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1 Introduction and Goals  
1.1 Introduction 
In 1953, James D. Watson and Francis Crick revealed the structure of “the molecule of life”. 
The discovery of the Deoxyribonucleic acid (DNA) structure was a breakthrough in molecular 
biology and opened up the way for what we know as biopharmaceutical manufacturing 
nowadays. After the DNA structure was revealed one significant discovery was followed by the 
next one: In 1956, Arthur Kronberg discovered the DNA polymerase as being the enzyme that 
synthesizes the DNA. In 1958, John C. Kendrew described the complex structure of the protein 
myoglobin. Francois Jacob and Jacques Monod discovered in 1960 how DNA can be 
transcribed to messenger ribonucleic acid (mRNA) that is translated to protein sequences.  
A second fundamental discovery in biotechnology, that led to modern biopharmaceutical 
processes, started with the development of a “DNA sequencing method” by Allan Maxam and 
Walter Gilbert.  Finally, Stanley Cohen and Herbert Boyer used the novel knowledge to create 
in vitro a new recombinant gene. In 1975, Goerges J.F. Köhler and César Milstein developed 
a method to produce monoclonal antibodies (mAbs) first with an in vivo production method and 
later on with in vitro production processes. mAbs are highly target-specific protein molecules 
used in diagnostics and as therapeutic drugs. Ultimately, this resulted in the first biotech 
company called Genentech going public in 1980. 
Even today mAbs are still the raising star within biopharmaceuticals. First-time approvals of 
mAbs raised from 27% (2010 – 2014) to 53% nowadays (2015 – July 2018). Because of their 
crucial role in diagnostics and cancer research, mAbs are one of the most important 
biopharmaceutical class for the future. Today mammalian cell lines, especially Chinese 
Hamster Ovary (CHO) cells, mainly serve as host for mAb production. Even though, mAbs 
became the most significant biopharmaceutical drug, the cell as production system is still 
considered as a black box. 
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To overcome the challenges in modern biopharmaceutical manufacturing and to better 
understand cell metabolism and process parameter correlations, the industry is moving 
towards high-throughput, small scale and single-use systems offering significant cost 
advantages and flexible experimental designs. Scalability in both directions (scale-down and 
scale-up) plays a key role in efficient bioprocessing to provide process understanding on the 
one hand and economic production processes on the other hand. Combined with the trends of 
process intensification and automation a better process understanding should lead to 
autonomous production laboratories of the future enabling fast access of new and safe 
biopharmaceuticals for patients. 
To optimize current bioprocess development the Food and Drug Administration (FDA) 
launched the Quality by Design (QbD) guideline to implement high and consistent product 
quality already during the development of new drugs. A toolbox allowing for QbD are Process 
Analytical Technologies (PAT). PAT tools support process understanding, online monitoring 
and automated control strategies in many different ways, e.g. the integration of spectroscopic 
inline sensors, the application of Multivariate Data Analysis (MVDA) or advanced risk analysis.   
1.2 Goals 
The goal of this work is to combine the novel industry approaches such as process 
intensification, single-use bioreactors and PAT tools to support the scalability of 
biopharmaceutical processes and to gain deep process understanding by innovative solutions. 
As a first step an established fed-batch process is transferred to a semi-perfusion process 
keeping the bioreactor equipment and available medium and feeds the same. This way, an 
established process platform can be utilized for further process intensification. The 
establishment of the new semi-perfusion process includes PAT tools like Design of Experiment 
(DoE). Proof of principle in an automated small scale, single-use bioreactor is investigated that 
can be used for early process development in future. Moreover, online PAT sensors for 
important process attributes or parameters (e.g. viable cell concentrations, VCC) are 
implemented into mammalian cell culture processes to enable real-time monitoring for a better 
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understanding of the process and the cell culture. This PhD work contributes to implement 
control strategies in future, such as automated feeding rates in fed-batch processes or 
perfusion rate control in intensified processes.  
Overall, the benefits of robust scale-down models, especially in process and method 
development, are highlighted and scale-independency of the selected PAT tools are 
investigated. Through the implementation of the developed methods in this work, a 
biopharmaceutical manufacturer will be supported to intensify and automate his single-use 
facility from laboratory up to production scale. 
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2 Theoretical Background 
2.1 Biopharmaceutical Manufacturing 
mAbs are key molecules in modern research and therapeutic areas. Because of their universal 
binding capability with a high precision to the target molecule, mAbs are frequently used in 
diagnostics or clinical research such as an anticancer drug or against autoimmune diseases 
[1–3]. However, the production of mAbs is a challenging and demanding task. The correct 
antibody quality is essential for their therapeutic activity and the risk reduction of causing any 
biological harm. As bioassays or even animal assays cannot be performed for every 
pharmaceutical product or batch, physical features or chemical structures serve as criteria to 
judge the quality of mAbs (e.g. post-translational modification). One important post-
translational modification of a mAb is the glycosylation pattern. Glycans affect solubility, 
pharmacokinetics and they are critical for biological activities. The need for a specific 
glycosylation pattern leads to mammalian cells as being the workhorse for mAb production [4–
6]. 
Mammalian cells are able to produce complex molecules with post-translational modification 
resulting in similar protein structure compared to equivalent produced molecules in human 
bodies. Another benefit of mammalian cells as production host of mAbs is that the protein is 
often secreted into the medium resulting in easy processing and purification of the product. 
Commonly used expression systems in research and industry are CHO cells, Baby Hamster 
Kidney (BHK21) cells, or murine myeloma cells [7, 8]. 
For the expression of mAbs in mammalian cells a suitable production system is necessary. 
Bioreactors offer the possibility to grow mammalian cells under controlled conditions. Several 
bioreactor types exist that underlie different basic principles of how the bioreactor is controlled 
and performed. Plug flow reactors (PFR), stirred tank reactors (STR) and rocking motion 
bioreactors are commonly used systems [9]. There are different types of processes for a 
mammalian cell cultivation, depending on the cultivation mode. Batch processes are short 
processes where the cell culture and all medium components are inside the bioreactor from 
2 Theoretical Background   
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the beginning. Thus, the bioreactor volume is kept constant over the complete cultivation time. 
Nutrient levels in a batch process decrease constantly and inhibiting metabolites, such as NH4 
or lactate accumulate over the process time. The most common used cell culture processes 
are operated in fed-batch (FB) mode. A FB process consist of a short batch phase and is 
followed by feeds of nutrients. The feeding rates are optimized based on the cells’ needs and 
the current growth phase. Thus, the nutrient level is adjusted based on the cell metabolism. 
Inhibiting metabolites, however, accumulate in the bioreactor. The bioreactor volume is 
increasing over time and the cell growth is expected to be higher compared to a batch process. 
A third way of cultivating cells inside a bioreactor is in perfusion mode. A perfusion process 
consists of a continuous exchange of medium and feeds during a process including a cell 
retention device. Therefore, the cells are kept in the bioreactor with a constant supply of fresh 
nutrients and inhibiting metabolites are constantly removed. The volume is kept constant but 
a high cell growth and productivity can be expected. In contrast to batch and FB processes, 
the product can be harvested continuously if the product is secreted into the medium, offering 
advantages for unstable molecules (e.g. recombinant Factor VIII) [9]. In the last years, the 
bioreactor equipment drastically improved enabling perfusion processes to be back in the 
focus of the pharmaceutical industry and academia [10–12]. The suitable combination of the 
bioreactor and operation mode depends on the cell type, the specific product and the available 
equipment.  
Besides the trend of intensifying the operation mode with perfusion processes, other trends 
and technical developments have significantly changed the research in biopharmaceutical 
manufacturing in the recent past. The industry moved from the classical stainless steel 
bioreactors towards single-use facilities offering high flexibility, lower cross contamination 
risks, fast time to market and a cost reduction [13–15]. However, a transfer from established 
processes, methods and bioreactor setups is not easily done when moving from stainless steel 
to single-use facilities.  
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Moreover, the development of high-throughput small scale bioreactors offers the flexibility for 
a fast process development and to gain intensive process understanding keeping experimental 
costs low and parallelizing and automatizing the work [16–18]. However, the scalability of the 
established processes is still a key step towards successful manufacturing. Only a process 
that reaches production stage meets the patients´ needs and is economical convenient. The 
following chapter gives a detailed overview of the scalability of biopharmaceutical processes. 
2.2 Scalability of Upstream Manufacturing Processes 
The main goal of a biopharmaceutical process is to achieve a robust and economic process 
with a constant, reproducible and high product quality in production scale. To achieve the goal, 
the development process can be divided into three stages. In a first step, the process 
development takes place in a laboratory scale. Main targets at this scale are a fast screening 
of cell lines, process parameters and operation modes. After the establishment of a robust 
process, first tests in pilot plants do follow. The pilot plant enables to define optimal operating 
spaces and process conditions. However, clinical trials in phase I/II/III of the novel drug need 
several kg of product. Thus, a scale-up to larger bioreactors is necessary to achieve an 
approved biopharmaceutical. The final biopharmaceutical process is transferred to production 
scale. The product can be produced economically for commercial applications only in 
production scale [19]. However, scalability is not one directional. The scale-up from small to 
large scale is as important as the establishment of a suitable scale-down model [20]. Therefore, 
each bioreactor from laboratory scale until production scale plays an important role in the 
scalability. Figure 1 gives an overview of a single-use bioreactor family from small scale 
(0.15 L) to large scale (2000 L) systems.   
For all these steps, scalability between the different bioreactor sizes is essential. The product 
quality as well as cell productivity and the cellular physiological states need to be kept constant 
in all bioreactors. A scalable process symbolizes a good prediction of the process performance 
and a specification of operating conditions switching from one scale to the other [6, 21].  
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Figure 1 Overview of a single-use bioreactor family (0.15 L - 2000 L) of Sartorius Stedim Biotech GmbH. [22] 
When scaling up bioprocesses the geometry of the bioreactors can either be similar or non-
similar. Similarity of bioreactors describes the ratios between the main parts being responsible 
for the chemical and physical environment of the bioreactor, such as the ratio height over 
diameter or the impeller configurations. In bioreactors of different sizes that are geometrically 
scaled, all length dimensions are scaled proportionally to the bioreactors scale. However, the 
change of bioreactor size can influence and change the chemical and physiological 
environment for the cells inside the bioreactor leading to unfavorable cell reactions or product 
qualities. Table 1 gives an overview of important biological, chemical or physical factors that 
influence the scaling approaches of cell culture processes. Major effects of the bioreactor scale 
are detected on the oxygen gas transfer, the shear forces for the cells, the compression force, 
the heat transfer in the bioreactor and the CO2 removal [6].  
Table 1 Summary of different factors that influence the scalability of mammalian cell culture processes 
Biological factors Chemical factors Physical factors 
Contamination risk  Carbohydrate concentration Aeration 
Mutation probability Foam formation  Agitation  
Number of generations 
Pellet formation 
Medium quality  
Nitrogen concentration 
Back pressure 
Heat transfer 
Selection pressure pH control agents  Hydrostatic pressure 
 Product concentration  Medium sterilization 
 Redox potential Mixing 
 Water quality Tank configuration 
Temperature control 
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Several classical scaling factors are suggested to be kept constant during a scale-up of 
mammalian cell cultivations, such as mixing time, volumetric oxygen transfer coefficient (kLa), 
power input per unit volume of liquid (P/V), Impeller Reynolds number (Rei) and superficial gas 
velocity [9, 19, 23–25].  
A constant power input per unit volume of liquid is a frequently used scaling approach. The 
power input is dependent on the impeller power (P0) as described in the following equation 
(Eq. 1) [26].  
0ܲ =  ௉ܰ ܰ3ܦ�5�         (1) 
NP is the Power number, N is the impeller speed, Di is the impeller diameter and p describes 
the fluid specific gravity. Keeping the power input per unit volume constant has several effects 
on other important process and bioreactor parameters. The agitation rate decreases with 
increasing scale. The impeller tip speed increases with an increase of the bioreactor scale. 
Mixing times increases with increased scales and the pumping capacity per volume decreases 
with increased scales [26]. 
The oxygen transfer rate (OTR) is another key aspect when scaling from one bioreactor to 
larger bioreactors. The OTR depends on the mass transfer coefficient (kLa) and the driving 
force (CO2∗ −  CO2), described in the following equation (Eq. 2). CO2∗  is the broth DO 
concentration at saturation and CO2is the measured broth DO concentration [27, 28]. ܱ�� = ��� ሺܥை2∗ − ܥை2ሻ    (2) 
Equation 2 indicates that high OTRs can be achieved with an increase in the mass transfer 
coefficient (kL), the interfacial area (a) or the driving force. Additionally, pure oxygen can be 
used to improve OTR. However, the sparging in the bioreactor influences the CO2 removal and 
therefore OTR changes need to be balanced based on the interaction of parameters [28].  
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To conclude, a bioreactor is a complex system and each parameter is connected and 
influenced by each other. Therefore, keeping all parameters constant during scale-up is difficult 
and many times compromises are needed.  
To understand the complexity of all parameters in the process, robust small scale models can 
offer big advantages. Therefore, in the last time the tendency in academia and industry led to 
miniaturized stirred tank reactors. Recently, bioreactors of sizes below 1 L working volume 
gained intensive interest for process development. The scalability between such small scale 
bioreactors and production bioreactors is a challenging task that needs to be investigated. In 
the following, recent scale-down and scale-up approaches will be further discussed.  
2.2.1 Scale-Down Approaches 
Early process development and characterization in biopharmaceutical manufacturing requires 
many experiments, leading to high development costs, resources and long development 
timelines. Recently, the interest in high-throughput small scale bioreactors increased 
significantly, because these bioreactors offer a solution to both development drawbacks: 
development costs and timelines. The highly parallel, single-use bioreactors with working 
volumes below 1 L enable fast process development and reduce the overall costs of 
experiments (e.g. applying DoE studies). 
Scale-down is far more than a simple reversion of the scale-up in biopharmaceutical 
manufacturing [21]. Scale-down models are not only advantageous for process development 
and characterization. Once a process reached pilot plants or production plants a robust small-
scale model can improve the process understanding, such as being a troubleshooting tool for 
root cause analysis of failures that occurred in large scale bioreactors. 
One system offering the possibility of developing robust small scale models of mammalian cell 
culture is the ambr® 250 bioreactor system. These highly-parallel, small scale bioreactors were 
selected in many novel studies to compare scale-up from laboratory scale to 1000 L 
bioreactors. The performance of the scale-down model was comparable in regard to process 
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performance and product quality in fed-batch mammalian cell culture processes [29–33]. The 
ambr® 250 system offers advantages when used as scale-down model. The volume of the 
bioreactors is low (0.25 L), but important scalability factors can be considered already in the 
scale-down model. The bioreactor is geometrically similar to large systems and process 
parameters, such as pH, DO, stir speed and temperature can be individually controlled for 
each bioreactor [17]. 
However, the availability of data sets for the scalability between the high-throughput, small 
scale bioreactors compared to commercial bioreactor scales of 2000 L and higher is limited. 
Manahan et al. successfully demonstrated for the first time the ambr® 250 as a scale down 
model for two commercial CHO cell lines producing mAbs in bioreactors larger than 10,000 L 
[17]. 
As already mentioned, the industry moves towards continuous manufacturing and perfusion 
process. The development costs for such processes without a scale-down model are high. A 
small-scale system can significantly improve perfusion development and increase the 
possibilities. Especially in process development and cell line screening, small scale bioreactors 
reduce costs and resources. Sewell et al. demonstrated that the automated ambr® 15 system 
with bioreactor volumes below 0.015 L represents a profitable process development tool being 
used for pseudo-perfusion processes [18]. 
To conclude, a robust small-scale process enables fast development at low costs and 
resources. Therefore, the biopharma industry can provide new treatments and medicine faster 
to the patients and positively impact their life. The potential of high-throughput, single-use, 
small scale bioreactors will impact the future of biopharmaceutical manufacturing, even though 
still many challenges do exist when scaling from smaller volumes in process development to 
production scale. A lot more research on miniaturized systems is necessary and the limitations 
need to be carefully considered [21]. 
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2.2.2 Scale-Up Approaches 
Due to the limitations in the configuration and design of large scale bioreactors, three main 
scale-up strategies for mammalian cell culture are established: (1) Constant kLa and constant 
specific impeller pump rate; Geometric similarity (2) Constant kLa and constant maximum 
shear; Geometric similarity (3) Constant kLa, constant impeller tip speed and constant impeller 
pump rate [19, 34–36]. 
The three scale-up strategies match with the most important needs of the cell culture. The 
main critical factors for cell cultures are oxygen supply, mixing times and CO2 removal.  
The oxygen supply to a mammalian cell culture is a critical factor as the process is aerobic. 
However, a simple increase in power input is not possible as many mammalian cell lines are 
shear sensitive. The development and use of surfactants such as poloxamers reduced shear 
stress and bubble damage supporting scalability for mammalian cell cultures [36, 37]. 
Nevertheless, the agitation rate constrains the scale-up of cell culture processes.  
The relatively low agitation rates and power inputs impact another critical factor, the mixing 
time. Process parameters such as pH or nutrient levels can form gradients with insufficient 
mixing in large scale bioreactors [36, 38].    
Xhu et al. experienced variations in cell growth, viability and productivity during their scale-up 
study with an increasing partial pressure of CO2 (pCO2) in large scale bioreactors [39]. In an 
extended scale-up study of the same group a 5000 L bioreactor was characterized resulting in 
longer mixing times, lower oxygen transfer and lower pCO2 removal rates for the large scale 
bioreactor [36]. The study revealed that an increase in bottom air sparging was more efficient 
than an increase in the power input in regard to oxygen transfer and pCO2 removal rates.  
Brunner et al. demonstrated in their scale-up studies that pH, DO and pCO2 variations have a 
strong impact on cell growth and productivity [40]. Moreover, this study revealed that pH and 
pCO2 interactions impact the product quality.   
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To conclude, for scalability of CHO cell cultures the deep understanding of how cell metabolism 
and productivity respond to process parameters variations is essential. Process scale-up can 
favor unwanted changes in the chemical environment of the cells such as pH variations that 
leads to changes in the cell productivity or product quality [36, 40–42]. To reduce the risk of 
failures during process scale-up advanced online monitoring and control tools need to be 
available and comparable in all bioreactor scales.  
Therefore, besides the classical scaling factors, PAT enables a deep understanding on how 
scale translations affect the process. Thus, PAT tools can improve the scalability between 
different bioreactor sizes. The following chapter provides a detailed description of PAT tools. 
2.3 Process Analytical Technology 
The International Conference on Harmonization (ICH) launched the ICH Q8 guideline in 2004 
including the QbD initiative to improve and sustain high quality in the development of 
pharmaceutical products [43]. The QbD guideline supports systematic approaches including 
continuous risk assessments, the identification of product attributes that are of significant 
importance to the product’s safety and establishment of robust control strategies to ensure 
consistent process and product performance [44]. Main goal of the QbD approach is to monitor 
and control Critical Process Parameters (CPPs) that influence Critical Quality Attributes 
(CQAs) of the pharmaceutical product to prevent variations in the CQAs. QbD implementation 
leads to a well-controlled manufacturing process within a pre-defined design space avoiding 
the detection of critical deviations after completion of the production processes. 
PAT is a toolbox that facilitates the process control aspect of QbD. The FDA launched the PAT 
initiative in the same year as the QbD guideline. PAT tools enable the establishment of 
consistent process performance, process control strategies and high product quality by 
monitoring and controlling CPPs in the complete life cycle of a manufacturing process [45–47]. 
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The PAT toolbox consists of many different parts that can be applied to a pharmaceutical 
process including software tools (e.g. Design of Experiments or Multivariate Data Analysis) or 
advanced process analyzers for online monitoring (e.g. Capacitance measurement).  
PAT tools cover different steps from designing experiments, analyzing the process, monitoring 
CPPs and finally online control to achieve a robust, reliable and consistent process 
performance from cell line development until fill and finish of the product. The advantages of 
PAT tools are obvious: enhanced process understanding, improved product yields, prevention 
of process failures, cost savings and the possibility for real-time release of products [48–51]. 
For chemical processes PAT is commonly applied and already integrated into FDA approved 
processes including real time releases [52]. However, the integration of PAT tools into 
biopharmaceutical processes is a challenging topic. Besides the sterility and integration of 
inline, online and at-line sensors into complex bioreactors, the transition to single-use systems 
and the scalability through all bioreactor systems represent demanding tasks for the industry. 
A biopharmaceutical upstream process with mammalian cells consists of many different 
reactions, production and consumption of several nutrients at the same time and the cell and 
its metabolism is still partially seen as a black box [44, 52]. Because of these challenges and 
the complexity of protein production, PAT tools and their integration are crucial to move from 
a black box towards a well-controlled process. 
In the last years, many attempts have been done to integrate different PAT tools into 
biopharmaceutical processes. Rowland-Jones et al. demonstrated in a powerful way how DoE 
can lead to a fast and efficient approach to create a design space in cell line screening and 
compare different PAT tools for online monitoring of nutrients such as ammonia, glucose and 
lactate in small scale systems [53]. Within the three selected PAT tools Near-Infrared (NIR), 
2D-Fluorescence and Raman spectroscopy the Raman spectroscopy offered best results in 
the investigated CHO process.  
Raman spectroscopy was successfully tested in many other applications including large scale 
bioreactors or downstream processing [54–59].  
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Furthermore, NIR, 2D-Fluorescence and other PAT tools such as online High Performance 
Liquid Chromatography, at-line Fluorescent Activated Cell Sorting or soft sensors were 
investigated for online monitoring of CPPs in a variety of production processes [52, 60–64]. 
Recently, Moore et al. reported for the first time the integration of a capacitance sensor into a 
commercial mammalian cell culture process being implemented as online tool to control seed 
train inoculations or feeding rates [65]. Capacitance sensors are preferred tools and frequently 
used to monitor online biomass related changes in the cell broth [66–72]. Key benefits are their 
easy integration into the sterile setup of a bioreactor and relatively low implementation costs 
[65, 73, 74].  
Even though the PAT initiative was published 2004 and many work has been done already, 
the integration of PAT tools into industrial processes remains a big challenge and more 
research to achieve standardized and reliable solutions is needed.  
2.3.1 Design of Experiments 
In the beginning of every new process development the question arises on what the optimum 
conditions look like and how they can be found. The number of process settings can easily 
exceed three process factor combinations when looking at complex processes, such as 
mammalian cell cultivation for mAb production: the cell line, medium and feed medium or 
process conditions, such as temperature, DO or pH are some examples that need to be 
considered at defined process development steps. Many times the best combination of 
process factors, that achieves a high product yield, is not sufficient. Other requirements might 
include establishing a process with the lowest possible costs and high product quality with 
short production times.  
The QbD approach aims at defining an optimal normal operating space within a defined design 
space of a manufacturing process. Figure 2A illustrates the understanding of a design space. 
A design space is a well-understood process range within the investigated knowledge space. 
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After the definition of the design space, the process can be performed in a controlled space 
within the design space.  
In mammalian cell culture processes univariate analysis of each parameter is complex and 
demanding with the requirement of a large number of experiments. Development times and 
costs do not allow for such approaches to identify the optimal design space. DoE however, 
aims at keeping the experimental work as low as possible and increases the understanding of 
the process response and data at the same time. The selection of characteristic parameter 
combinations, application of mathematical modelling and statistical methodologies optimize 
the process to move from the knowledge space towards the design space in a systematic way 
[75]. Therefore, DoE applications can be used as powerful tools to save costs, resources and 
time, while gaining deep information about the process.  
There are three different basic problems where DoE is commonly applied: Screening, 
optimizing and robustness testing [76]. The purpose of screening DoEs is to identify most 
influential parameters within the investigated process. Moreover, screening DoEs analyze the 
knowledge space and give indications about the parameter ranges that are applicable to the 
process. In early process development of pharmaceutical manufacturing a screening DoE can 
be used to screen for different media components, the ratio between each components and 
the right feeding times of the nutrients to maximize product yield and quality [77–80]. After 
screening an optimization DoE is commonly applied to find the optimum within the design 
space based on previously determined responses and CQAs. In many complex cases the 
optimum is defined by a compromise that maximizes the outcome while considering all 
parameters and response factors. In a mammalian cell culture process an optimization DoE 
can be applied to optimize bioreactor settings such as pH, temperature or DO set points [40, 
81, 82]. The last step of a DoE investigation consists of robustness trials that demonstrate the 
ruggedness of the process towards expected inevitable parameter variations at the chosen set 
points inside the design space under which the process results in CQAs within acceptable 
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ranges. Questions in regards to product specification and reproducibility of the results are 
covered within robustness trials. 
The DoE design depends on the scope of the experiments and the amount of investigated 
parameters. However, the amount of experiments needed and information received by the 
DoE strongly depends on the selected DoE design. Commonly used designs (full factorial, 
fractional factorial and composite designs) are summarized in Figure 2B [75, 76, 83, 84]. 
 
Figure 2 A Schematic description of the definition for knowledge space, design space and control space/normal 
operating space. B Selected DoE designs for 2 or 3 factors. 
In the last years, DoE became the method of choice to improve process understanding and 
speed up development processes in academia as well as in industry. Therefore, many 
examples of DoE applications, especially in biopharma, can be found in the literature [85–90].  
2.3.2 Multivariate Data Analysis 
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The complexity of data generated during a biopharmaceutical process is continuously 
increasing. High-throughput, automated small scale bioreactors, the implementation of DoEs 
and integration of PAT tools into each process intensify the need for systematic and 
multivariate analysis of the available data sets to separate and understand overlapping effects 
and parameter relations. Improved process knowledge cannot be acquired by univariate data 
analysis. MVDA is a proposed key method to accomplish the PAT and QbD guidelines in 
pharma processes by reducing and classifying the data and separating important information 
from noise [91]. MVDA allows for a detailed process understanding and delivers relevant and 
crucial process information by analyzing large data sets and enabling easy interpretation of 
complex parameter relationships [45, 46].  
Traditional MVDA methods were used for a diverse range of problem statements in varying 
industries. The methods include multiple linear regression, linear discriminant analysis, 
canonical correlation or factor analysis [92, 93]. These methods were applied to independent 
and conditioned variables. Pharmaceutical processes are complex and variables might be 
driven by a few inherent and latent variables compared to the overall number of observed 
variables. One simple approach to overcome these challenges within pharmaceutical 
processes is the implementation of MVDA projection methods such as Principle Component 
Analysis (PCA) and Partial Least Squares projections to latent structures (PLS). Both 
approaches aim at reducing the number of variables in a k-dimensional space down to a lower-
dimensional space or hyper-plane [93].  
One basic method behind MVDA is PCA [93–96]. As described in Figure 3A, for PCA the 
experimental data is summarized in a matrix consisting of K variables and N observations.  
The variables represent the data from a pharmaceutical manufacturing process, such as data 
from pH and temperature sensors, chromatographic methods or spectroscopic PAT tools (e.g. 
Raman, NIR or capacitance frequency scanning) [59, 91, 97].  
PCA reduces the dimensionality of the data set by integrating lines, planes and hyperplanes 
in the K-dimensional space and applying the least square approximation while keeping as 
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much information as possible about the variation of the data. Therefore, the original data set 
is transferred into a set of uncorrelated variables, the Principle Components (PCs). Figure 3 B 
demonstrates the principle of establishing PCs with the least square approach. Commonly, 
PC1 describes the largest variation of the data set. Each following PC is orthogonal to the 
existing PCs until the amount of PCs is sufficient to describe the variation in the complete data 
set. The coordinate value along the PC-line generated by the projection of an observation onto 
the PC-line is defined as score. The PCA approach can reveal groups of observations, trends, 
and outliers and defines relationships between observations and variables [92, 93].  
 
Figure 3 A Overview of data matrix for MVDA analysis. B Determination of the first and second principle component 
(PC) in a coordinate system using the least square approach. Each data point is defined as observation. The 
coordinate value along the PC-line generated by the projection of an observation onto the PC-line is defined as 
score. Based on the PCs a new reduced coordinate system is defined.   
One drawback of PCA is that the method reduces unsupervised the dimensions in the 
variables. In contrast to PCA, PLS offers the possibility to link the information of two data 
matrices by a linear multivariate model, where one matrix is assigned to the variables (also 
called predictors) and the other matrix belongs to the responses. Thus, PLS enables analysis 
of collinear or even incomplete variables in both matrices and can be seen as a regression 
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method to model the association between the predictors’ matrix and the response matrix [93, 
98].  
MVDA is frequently used in biopharmaceutical manufacturing to increase process 
understanding and knowledge [44, 46, 99–101]. Moreover, MVDA enables online monitoring 
and control of process responses (e.g. CPPs) based on selected variables, such as 
spectroscopic sensor data [63, 64, 74, 97].  
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3 Results and Discussion 
This doctoral thesis can be separated into three different parts that are closely linked to each 
other. Each part was published separately in a peer-reviewed journal. 
The first publication named “A protocol to transfer a fed-batch platform process into semi-
perfusion mode: The benefit of automated small scale bioreactors compared to shake flasks 
as scale-down model” focuses on process intensification. Process intensification and 
continuous manufacturing are upcoming trends in biopharmaceutical manufacturing. Due to 
the increasing number of new biopharmaceuticals and a high pressure for low cost 
manufacturing, the industry is moving towards development of high yielding processes with 
consistent product quality. To achieve the ambitious goals PAT tools and small scale 
bioreactors are crucial.  
The publication demonstrates how DoE as a PAT tool enables a powerful and fast 
development of a semi-perfusion process based on an established fed-batch process platform. 
Therefore, the method can be used to transfer existing process platforms to intensified 
processes with significant increase in product yield while keeping the same process timelines. 
A simple increase in nutrient supply was beneficial for high cell counts as long as the medium 
composition did not exceed the physiological limits of the cells (e.g. high osmolality). Finally, 
the new established semi-perfusion process was transferred to an automated, high-throughput 
bioreactor system. The proof of concept in the miniaturized bioreactor empowers future 
development in a controlled bioreactor environment speeding up timelines, reducing costs and 
enabling deep process understanding for easy scale-up. 
The development of intensified mammalian cell culture processes reveals once again the 
importance of VCC as a process attribute. VCCs can be used for automation and control of 
perfusion processes, such as automated bleed or perfusion rates based on the online 
information about the cell growth. However, VCCs are still measured offline. 
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Therefore, the second part of the doctoral thesis focuses on the scale-independent 
development of a PAT tool for online monitoring of biomass related changes in cell culture.  
The publication “Monitoring online biomass with a capacitance sensor during scale-up of 
industrially relevant CHO cell culture fed-batch processes in single-use bioreactors” uses the 
capacitance measurement principle to correlate the permittivity signal with important biomass 
parameters: The Wet Cell Weight (WCW), the Viable Cell Volume (VCV) and the VCC. For 
method development an established and well-defined, industrial fed-batch process is used. 
The principle of capacitance sensors can be found in various literature under different names, 
such as radio frequency impedance, bio-capacitance, dielectric spectroscopy or multi-
frequency permittivity [73, 81, 97, 102–104]. A compact overview on the methodology used in 
this thesis is given in Carvell et al. [69].  
The principle behind capacitance sensors is the application of an electrical alternating current 
in the ionic cell solution. The ions in the highly conducting cellular cytoplasm move in the 
direction of the electrical field towards the non-conducting cellular membrane where their 
movement is limited. Thus, a charge separation within the cells take place and the cells 
polarize [69]. As a result, the measured capacitance is dependent on the polarizability of the 
cells that is linked to the cell properties. 
A capacitance sensor supplies information about the physical properties capacitance and 
conductivity of the sensor electrodes in interaction with the cell suspension. The capacitance 
and conductivity are frequency dependent and need to be combined with the cell constant of 
the sensor, taking the electrode geometry into account, to give information about the dielectric 
properties of the cells. Thus, the capacitance component of the sensor provides the permittivity 
signal of the cell suspension [105, 106]. 
As a result of the capacitance measurement principle, dead cells and other impurities in the 
cell broth are not polarizable as they have no intact cell membrane [69, 107]. Therefore, they 
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do not influence the measurement and the difference in permittivity can be correlated to viable 
biomass related changes.  
The second publication demonstrates scale-independency of the capacitance measurement 
principle in single-use bioreactors ranging from 50 L scale up to 2000 L bioreactor volume. The 
method is investigated for two different industrial fed-batch processes. As expected from the 
literature, the method is successful for WCW and VCV in both processes. However, the VCC 
correlation is limited to the exponential growth phase. As soon as a significant cell diameter 
change occurred, the correlation to VCC is not given with single-frequency measurements 
anymore. 
The polarizability of the cells is frequency dependent. Depending on the selected frequencies, 
the cells can either according to a given excitation completely polarize (leading to high 
permittivity) or the cell polarization is incomplete with increasing frequency (resulting in a 
decrease of permittivity). This phenomenon is described as ß-dispersion curve in literature 
[69]. Thus, measuring permittivity at one frequency leads to a cell diameter dependency. 
Changes in permittivity can result from changes in cell counts as well as constant cell counts 
with changes in cell diameters. 
To overcome the challenge of single-frequency measurements first attempts to measure 
permittivity at multiple frequencies in combination with mathematic modelling were applied in 
the recent past to online monitor VCCs [66, 74]. 
The third publication “Multivariate data analysis of capacitance frequency scanning for online 
monitoring of viable cell concentrations in small scale bioreactors” uses a method to combine 
MVDA analysis of frequency scanning data to correlate and predict online VCCs. The method 
is applied to one of the previous used industrial fed-batch processes. The MVDA model, 
including all frequencies, leads to a successful correlation and prediction of the VCC 
throughout the complete cultivation time. Moreover, the method development is done in a small 
scale bioreactor enabling fast and economic development timelines. The publication 
demonstrates once again the importance and benefits of suitable scale-down models in 
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combination with PAT tools. To conclude, the presented method on frequency scanning in 
combination with MVDA enables online monitoring of the important process attribute VCC. The 
method is proposed to be used as process control tool leading to improved process 
understanding and consistent process performance. 
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3.1 A protocol to transfer a fed-batch platform process into semi-perfusion mode: The 
benefit of automated small scale bioreactors compared to shake flasks as scale-down 
model (Biotechnology Progress, 2018) 
 
Figure 4 Graphical abstract of “A protocol to transfer a fed-batch platform process into semi-perfusion mode: The 
benefit of automated small scale bioreactors compared to shake flasks as scale-down model”. [22] 
 
Nowadays, the need for fast pharmaceutical development with high product yield and quality 
is increasing constantly. The following section focuses on process intensification to achieve a 
product yield increase within the same process time and by keeping the original equipment. 
Goal of the work was to develop in a short timeframe a semi-perfusion CHO process based on 
an existing conventional fed-batch process, increasing the product titer significantly, while 
keeping a healthy cell culture with end viabilities above 70%.  
The first step towards a semi-perfusion process was to identify the optimal medium 
composition based on the process medium and feeds of the conventional fed-batch. A DoE 
approach in shake-flasks enabled a fast medium screening with a low number of experiments. 
The optimal basic medium formulation consisted of 91.2% process medium, 8% feed medium 
A and 0.8% feed medium B. After the DoE identified the optimal medium composition for the 
semi-perfusion process, the glucose concentration was investigated and optimized. To deliver 
best nutrient supply to the high VCCs in the culture a glucose spike to keep the concentration 
above 2 g/L was implemented. Additionally, the cell bleed was investigated as it relates to the 
cell specific perfusion rate that influences the viability of the cell culture. The final semi-
perfusion process design was fixed to a cell bleed to 20 million cells/mL, a glucose spike to 
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keep the concentration above 2 g/L and the medium formulation revealed from the DoE 
studies. The cumulative mAb titer was successfully increased to 10 g/L being threefold higher 
compared to the conventional fed-batch process. 
The optimized semi-perfusion process was transferred from shake-flask to an automated, 
small scale bioreactor system offering a controlled bioreactor environment for important 
process parameters, such as pH or DO. In the small scale bioreactor the best overall result for 
the cell specific productivity (38.9 pg/(cell*day)) in contrast to semi-perfusion shake flasks 
(36.0 pg/(cell*day)) and the fed-batch process (24.2 pg/(cell*day)) was achieved. The 
microscale bioreactor represents a powerful scale-down system enabling early process 
development in controlled bioreactor environments. Thus, the media screening and process 
development takes place in an environment similar to the final production bioreactors. The 
presented method can be used for process intensification, saving costs and reducing the 
footprint of biopharmaceutical production plants. 
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3.2 Monitoring online biomass with a capacitance sensor during scale-up of industrially 
relevant CHO cell culture fed-batch processes in single-use bioreactors (Bioprocess and 
Biosystems Engineering, 2019) 
 
Figure 5 Graphical abstract of "Monitoring online biomass with a capacitance sensor during scale-up of industrially 
relevant CHO cell culture fed-batch processes in single-use bioreactors". [22] 
 
VCC is an important process attribute in all mammalian cell culture processes. The previous 
section demonstrated the great potential of process intensification leading to high product 
yields. Perfusion processes require a high degree of process understanding and automation. 
Online monitoring of VCCs can be used for cell bleed adaption or for perfusion rate automation. 
However, VCC is still measured offline limiting the opportunities for the further development 
and automation of the semi-perfusion process. The offline sample for VCC reveals additional 
drawbacks, such as low temporal resolution or high contamination risks due to interaction of 
the operator with the bioreactor. Therefore, this section focuses on the establishment of a PAT 
tool to monitor online VCCs. The method development required a scale-independent method 
for single-use bioreactors that can be applied to all different process types. Thus, a capacitance 
sensor operated in single-frequency mode was investigated to provide online information about 
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biomass related changes. For the proof of concept a well-established fed-batch platform was 
used and performed in all available single-use bioreactors from 50 L up to 2000 L. The 
permittivity signal was correlated to selected parameters (WCW, VCV and VCC) and a linear 
regression model served the online prediction of the parameters. The proof of concept was 
repeated with a second industrial relevant fed-batch process to give an indication about the 
method transferability.  
The linear regression model based on the inline capacitance sensor successfully monitored 
the WCW with a coefficient of determinations of 0.79 for Process A and 0.99 for Process B. 
The VCV correlated best to the permittivity signal with high coefficients of determination of 0.96 
(Process A) and 0.98 (Process B), respectively. However, the linear correlation between 
permittivity and VCC was only valid for the exponential growth phase. In agreement with 
literature results the regression model excluded values after the peak cell concentration. The 
linear regression for the exponential growth phase was successful for all cultivations with high 
coefficients of determination of 0.99 (Process A) and 0.96 (Process B), respectively. 
For all investigated parameters and in both fed-batch processes, no influence of the bioreactor 
size was observed. Therefore, scale-independency of the method was demonstrated offering 
a deep process understanding during future scale-up or scale-down. The presented method 
enables process control and online monitoring of important process parameters.  
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3.3 Multivariate data analysis of capacitance frequency scanning for online monitoring 
of viable cell concentrations in small scale bioreactors (Analytical and Bioanalytical 
Chemistry, 2019) 
 
Figure 6 Graphical abstract of "Multivariate data analysis of capacitance frequency scanning for online monitoring 
of viable cell concentrations in small scale bioreactors". 
 
The previous two sections successfully described how the combination of PAT tools and small 
and large scale models lead to process intensification and improved process understanding. 
After identification of VCC as an important process attribute for mammalian cell culture process 
(especially in perfusion processes), the capacitance sensor was evaluated and successfully 
implemented as a scale-independent tool for online monitoring of biomass related changes. 
However, a drawback of the single-frequency measurement method did not allow for a VCC 
prediction over the complete process time. Therefore, this section presents a novel 
methodology to optimize capacitance sensors applying frequency scanning and mathematic-
statistic modelling for online VCC monitoring.  
In this section, several standard fed-batch cultivations served as training set to develop a 
MVDA model that predicts the VCC from the frequency scan of the capacitance sensor with 
25 different frequencies. The MVDA model successfully enabled a VCC prediction throughout 
the complete cultivation time with relative errors ranging from 5.5% to 11%, which fulfils the 
acceptance criterion based on the offline reference method accuracy (approximately 10% 
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relative error). The prediction capabilities for VCC strongly improved with the MVDA model 
compared to single-frequency results (16% to 23% relative error). 
After the VCC MVDA model was established with standard fed-batch cultivations, robustness 
trials were conducted to investigate the model´s predictive ability under challenging conditions. 
The selected process deviations consisted of dilution steps in a first experiment and feed 
variations in a second robustness trial. All process deviations were detected immediately in 
the online prediction of the VCC with relative errors between 6.7% and 13.2%. The online VCC 
monitoring led to superior process information compared to the conventional offline reference 
method. A batch evolution model detected the feed variation immediately, whereas the 
corresponding offline reference did not reveal clear changes compared to the standard fed-
batches. 
The method development in a suitable scale-down model (single-use bioreactor with a volume 
of 0.25 L) was fast and economic including a sufficient amount of cultivations for a robust 
MVDA VCC model.  
To summarize, the combination of an inline PAT sensor, frequency scanning and MVDA in the 
mammalian CHO fed-batch culture enables online VCC prediction over a complete cultivation 
time being a major process attribute for future monitoring and control strategies. 
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4 Summary and Outlook 
Modern biopharmaceutical manufacturing aims at intensifying and automating mammalian cell 
culture processes in single-use facilities to reduce costs, increase product safety and deliver 
high flexibility in the facility.  
Scalability and online monitoring or control by PAT tools are crucial factors for fast and 
economic process development and deep process understanding. The implementation of PAT 
tools in all available bioreactor scales, starting from scale-down models up to production 
scales, enable advanced process monitoring, control and automation. Thus, PAT tools lead to 
consistent and high product quality following the QbD requirements of the FDA.  
The presented work focused on demonstrating the benefits of PAT tools in different single-use 
bioreactor scales to fulfill the industries’ needs for process intensification and automation. The 
application of DoE studies in high-throughput, small scale bioreactors enabled rapid process 
development of a semi-perfusion process with increased product yield. The presented method 
is a powerful tool that can be used to intensify existing fed-batch process platforms in future 
as well as to develop new perfusion processes. 
To further automate the presented cell culture processes a capacitance sensor was 
successfully investigated as online monitoring tool for biomass related changes (WCW, VCV, 
VCC) in single-use bioreactor volumes from 50 L up to 2000 L. Especially, the process attribute 
VCC requires a continuous measurement principle that can be used for automation, e.g. 
feeding rates in perfusion or fed-batch processes. However, VCC prediction was limited to the 
exponential growth phase with the single-frequency measurement mode of the capacitance 
sensor.  
Thus, the capacitance sensor was used in frequency scanning mode and the application of 
MVDA to the frequency scan optimized the online prediction of VCCs with great success. The 
MVDA model development was performed in single-use, small scale bioreactors resulting in a 
fast and low cost method development. The novel method can provide extensive process 
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understanding and lead to powerful control strategies. As a future step, the transferability of 
the developed VCC MVDA model to larger bioreactor scales should be investigated.  
This work demonstrates that the combination of PAT tools and single-use bioreactors can 
positively impact the process development and understanding. The application range of the 
tools developed in this work is broad. First results of applying the tools in the process 
automation were recently presented at an international conference (ESACT 2019, Poster 
Matuszczyk et al.). A capacitance sensor that monitored online the VCC in the pre-culture, 
performed automated the inoculation of an n-stage bioreactor. The automation led to reduced 
operator handling and less contamination risks. However, further work is required in future to 
automate mammalian cell culture processes with the help of PAT tools. The establishment of 
autonomous production facilities with complete online monitoring and control remains an 
ongoing task. Future work of high interest is to develop a connected and automated cell culture 
process from cell thaw until downstream processing using the developed online PAT tools. 
Multi-parallel bioreactors with implemented PAT tools as small scale models can support fast 
troubleshooting and enable advanced understanding of process parameter interactions and 
their impact on product quality. The developed tools can be adopted and transferred to FDA 
approved biopharmaceutical manufacturing. Small scale systems and easy scale-up 
significantly reduce development timelines of new drugs resulting in faster clinical trials and 
finally faster access for patients to new pharmaceuticals. 
Even though the final implementation of these tools into FDA approved biopharmaceutical 
processes remains a challenge and regulatory work is needed, the high potential of these 
methods is driving the industry forward. This PhD thesis contributes to implement online control 
tools into mammalian cell culture processes that lead to autonomous laboratories of the future. 
The reduction of operator interaction in biopharmaceutical processes can significantly 
decrease the risk of failures in productions and increase a consistent product quality.
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